MET amplification was present in 15% of tumor samples from patients who were relapsing on next-generation ALK inhibitors, compared to 12% and 22% of tumor biopsies from patients who were progressing on second-generation inhibitors or lorlatinib, respectively. This evidence concerns the gene MET and neoplasm.